Excellent therapeutic response to pembrolizumab in a 51-year-old patient with metastatic urothelial carcinoma
HlavnĂ stanovisko prĂĄce: SdÄlenĂ poskytuje komplexnĂ pĹehled o moĹžnostech terapie generalizovanĂŠho uroteliĂĄlnĂho karcinomu. PrĹŻbÄh lĂŠÄby demonstruje modelovĂĄ kazuistika. Rekomendacea efekt lĂŠÄby jsou podpoĹeny aktuĂĄlnĂmi vĂ˝sledky klinickĂ˝ch studiĂ a v souladu s nejnovÄjĹĄĂmi doporuÄenĂmi EvropskĂŠ urologickĂŠ asociace.Souhrn: AutoĹi prezentujĂ pĹĂpad pacienta s metastatickĂ˝m uroteliĂĄlnĂm karcinomem, diskuÂtujĂ vĂ˝bornĂ˝ efekt imunoterapie pembrolizumabem v souvislosti s vĂ˝sledky komplexnĂho genomickĂŠho profilovĂĄnĂ nĂĄdorovĂŠ tkĂĄnÄ.
Authors
- Michal Fedorko (ORCID: https://orcid.org/0000-0001-6893-8829)
- Gabriel Varga (ORCID: https://orcid.org/0000-0003-2799-9283)
- Dávid Said
- Michal Eid (ORCID: https://orcid.org/0000-0002-4433-5326)
- Barbora Bošanská
Publication Details
- Journal
- Czech Urology
- Published
- 2025-03-24
- DOI
- https://doi.org/10.48095/cccu2025008
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00